Clearstead Trust LLC Has $571,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Clearstead Trust LLC grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1,714.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,340 shares of the medical instruments supplier’s stock after buying an additional 2,211 shares during the period. Clearstead Trust LLC’s holdings in Becton, Dickinson and Company were worth $571,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ontario Teachers Pension Plan Board boosted its holdings in Becton, Dickinson and Company by 242.8% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after purchasing an additional 1,263,391 shares during the period. Vanguard Group Inc. grew its position in Becton, Dickinson and Company by 2.0% during the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after buying an additional 516,427 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Becton, Dickinson and Company by 11.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock worth $1,342,503,000 after acquiring an additional 512,566 shares during the period. Royal Bank of Canada raised its holdings in Becton, Dickinson and Company by 28.5% in the 3rd quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after acquiring an additional 473,914 shares in the last quarter. Finally, Morgan Stanley lifted its position in shares of Becton, Dickinson and Company by 4.5% during the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after acquiring an additional 435,168 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Barclays raised their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $280.00.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded down $5.67 during trading hours on Friday, reaching $234.68. The company’s stock had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32. The firm’s 50 day simple moving average is $238.45 and its 200-day simple moving average is $240.53. The company has a quick ratio of 0.64, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $67.80 billion, a price-to-earnings ratio of 51.69, a PEG ratio of 1.98 and a beta of 0.45.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, beating the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. Becton, Dickinson and Company’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted $2.86 earnings per share. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.98 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is 83.70%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.